Physician profile
Jeffrey S Brackeen
NPI 1922290592
$13,022.40
in general payments reported to CMS, 2019-2025
32 companies · $1,338 in 2025
The $1,338 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,993 · 2020: $1,269 · 2021: $740 · 2022: $1,115 · 2023: $1,333 · 2024: $1,236 · 2025: $1,338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,679 · Education: $227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,679.16 |
| Education | $226.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $4,892.43 | 2019-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Abbvie INC. | $1,428.77 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $1,065.18 | 2019-2025 | Tremfya, Stelara, Simponi |
| Regeneron Healthcare Solutions, INC. | $803.08 | 2021-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $593.70 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Leo Pharma INC. | $514.77 | 2022-2025 | Adbry |
| Sun Pharmaceutical Industries INC. | $391.40 | 2019-2025 | Ilumya, Odomzo, Blu-U |
| Amgen INC. | $378.65 | 2020-2024 | Otezla |
| Mayne Pharma Commercial LLC | $302.00 | 2019-2022 | |
| Genentech USA, INC. | $297.45 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $238.54 | 2019-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $221.17 | 2019-2025 | |
| Ucb, INC. | $202.43 | 2024-2025 | Bimzelx |
| Pfizer INC. | $159.91 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $140.50 | 2019-2025 | Jublia |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $139.80 | 2025 | Vtama |
| Incyte Corporation | $137.63 | 2021-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $132.64 | 2023-2025 | Zoryve |
| Kerecis Limited | $128.95 | 2022-2024 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Dermavant Sciences, INC. | $127.40 | 2023-2024 | Vtama |
| Journey Medical Corporation | $120.80 | 2022-2023 | |
| Almirall LLC | $112.77 | 2023-2025 | Klisyri, Seysara |
| Genzyme Corporation | $86.00 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $84.72 | 2020 | |
| Lilly USA, LLC | $76.77 | 2019-2025 | Ebglyss, Taltz |
| Prugen, INC. Pharmaceuticals | $63.19 | 2019 | |
| Vyne Pharmaceuticals INC. | $53.96 | 2020 | |
| Aclaris Therapeutics, INC. | $34.72 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.15 | 2023 | Spevigo |
| Organogenesis INC. | $23.50 | 2025 | Affinity |
| Bioventus LLC | $21.65 | 2022 | |
| Celgene Corporation | $17.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Brackeen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.